Sanofi is conducting multiple studies for CIDP. Please complete a questionnaire to determine which studies you may qualify to participate in.
Check your eligibility now & get in touch with a study center
CHECK ELIGIBILITY
Have you been diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP)? Do you want to know more about clinical trials for in CIDP?
Do you want to know more about clinical trials for in CIDP?
What is chronic inflammatory demyelinating polyneuropathy (CIDP)?
CIDP is a rare condition where the body’s immune system attacks the myelin that covers and protects nerves. People with CIDP can experience tingling, numbness and muscle weakness, making the activities of daily living, such as walking, difficult. To find out more visit the CIDP Foundation.
What is the investigational medication?
An investigational medication is what is being studied to see if symptoms improve while taking it. It is not yet approved for general use by regulatory authorities. This study uses an investigational medication called Riliprubart. The investigational medicine is injected in a vein or under the skin, either at the clinic or at home (self-admistered). It blocks a particular part of the body's defense system from being overactive.
FAQs
What is a placebo?
What is a placebo?
A placebo is an inactive substance or treatment that looks the same and is given in the way as the investigational medication that is being studied.
Of the studies being conducted, one of the studies you will have a 50% chance of receiving either a placebo or the investigational medication initially. The other study you will have a 50% chance of receiving either intravenous immunoglobulin (IVIg) or the investigational medication in the beginning. Both studies will receive the investigational medication for the final 5 ½ months of the study.
What is expected during the study?
What is expected during the study?
Participation in this study means that you agree to follow certain study rules. This will also help to ensure your safety.
- Provide truthful information about your medical condition(s) and treatments(s) that you have been using for CIDP.
- Inform the study doctor before starting, modifying or stopping any treatment(s) for CIDP.
- Attend the scheduled visits and allow the tests or procedures to be performed.
- Inform the study doctor or study staff, as soon as possible, of any side effects or health problems even if you do not think they are related to the study.
- Complete a paper diary to report weekly at home injections and patient reported outcomes (PROs) at onsite visits.
Is there a cost to participate?
Is there a cost to participate?
All study-related medical care related to the study is provided, including study-related exams, study-related medications and other study-related medical care. There is no insurance required to participate. All study-related medical care will be explained.
Studies may also offer compensation for meals and travel (flights, car / rail services and hotels) when attending site visits as approved by ethics committees.
Am I Eligible?
Sanofi believes that everyone should have the opportunity to take part in clinical trials. It is important to include people who have been historically under-represented in clinical trials. Sanofi is committed to inclusivity in our studies.
If you are interested in learning more about these studies, we encourage you to complete this brief questionnaire to help determine if you may qualify to participate and be referred to a site recruiting in your area for further evaluation.
Preview complete
The prescreener preview is complete. You may now close the preview.
Version 1,0, 21Aug2024
Images property of Sanofi